Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -21.36% | 42.91% | -72.90% | ||
| Total Depreciation and Amortization | 127.15% | 23.77% | 49.06% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -89.30% | 226.19% | 40.52% | ||
| Change in Net Operating Assets | 152.39% | -581.16% | 82.18% | ||
| Cash from Operations | 87.39% | -61.77% | -7.24% | ||
| Capital Expenditure | 98.28% | -138.68% | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -9,031.89% | -138.68% | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -100.00% | 1,397.71% | 9.64% | ||
| Cash from Financing | -100.00% | 1,397.71% | 9.64% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -172.88% | -- | -- | ||